Powelldidriksen1004

This article presents behavior and EEG dataset collected from 19 healthy human volunteers (10 females) in the age group of 21-29 (mean = 26.9, SD = ±2.15) years at National Brain Research Centre, India during a psychophysical paradigm customized to characterize the brain network interactions during saliency processing. We provide all the raw stimulus files used in developing the experimental paradigm of the linked research article "Organization of directed functional connectivity among nodes of ventral attention network reveals the common network mechanisms underlying saliency processing across distinct spatial and spatio-temporal scales" [1] for replication and use by researchers across various cohorts of the population. Pre-processed EEG time-series segmented into epochs corresponding to three experimental trial conditions, across two visual attention tasks testing the effect of salient distractors on goal-driven tasks are provided. The dataset also includes reaction times corresponding to individual trials. Additionally, structural MRI files corresponding to each individual and 3D EEG sensor locations of all volunteers are provided to assist in accurate source localization. Therefore, the presented dataset will not only facilitate the conventional time resolved EEG analysis like evoked activity and time-frequency analysis at the sensor level but will also facilitate the investigation of source level analysis like global coherence or phase-amplitude coupling within selected regions of the brain.Transcranial alternating current stimulation (tACS) can affect perception, learning and cognition, but the underlying mechanisms are not well understood. A promising strategy to elucidate these mechanisms aims at applying tACS while electric or magnetic brain oscillations targeted by stimulation are recorded. However, reconstructing brain oscillations targeted by tACS remains a challenging problem due to stimulation artifacts. Besides lack of an established strategy to effectively supress such stimulation artifacts, there are also no resources available that allow for the development and testing of new and effective tACS artefact suppression algorithms, such as adaptive spatial filtering using beamforming or signal-space projection. Here, we provide a full dataset comprising encephalographic (EEG) recordings across six healthy human volunteers who underwent 10-Hz amplitude-modulated tACS (AM-tACS) during a 10-Hz steady-state visually evoked potential (SSVEP) paradigm. Moreover, data and scripts are provided rr testing different artifact rejection methods and offers in-depth insights into the workings of SASS.The coronavirus pandemic could be the most threatening outbreak in the twenty-first century. According to the latest records of world health organization, more than 130 millions have been infected by COVID-19, with more than 2.9 million reported deaths. Yet, there is no magic cure for treatment of COVID-19. The concept of drug repurposing has been introduced as a fast, life-saving approach for drug discovery. Drug repurposing infers investigating already approved drugs for new indications, using the available information about pathophysiology of diseases and pharmacodynamics of drugs. In a recent work, more than 3000 FDA approved drugs were tested using virtual screening as potential antiviral agents for COVID-19. In this work, the top ranked five hits from the previous docking results together with drugs of similar chemical feature and/or mechanistic destinations were further tested using AutoDock Vina. The results showed that anti-HCV combinations could be potential therapeutic regimens for COVID-19 infections.

The online version contains supplementary material available at 10.1007/s13337-021-00691-6.

The online version contains supplementary material available at 10.1007/s13337-021-00691-6.More than any other infectious disease epidemic, the COVID-19 pandemic has been characterized by the generation of large volumes of viral genomic data at an incredible pace due to recent advances in high-throughput sequencing technologies, the rapid global spread of SARS-CoV-2, and its persistent threat to public health. However, distinguishing the most epidemiologically relevant information encoded in these vast amounts of data requires substantial effort across the research and public health communities. Studies of SARS-CoV-2 genomes have been critical in tracking the spread of variants and understanding its epidemic dynamics, and may prove crucial for controlling future epidemics and alleviating significant public health burdens. Together, genomic data and bioinformatics methods enable broad-scale investigations of the spread of SARS-CoV-2 at the local, national, and global scales and allow researchers the ability to efficiently track the emergence of novel variants, reconstruct epidemic dynamics, and provide important insights into drug and vaccine development and disease control. find protocol Here, we discuss the tremendous opportunities that genomics offers to unlock the effective use of SARS-CoV-2 genomic data for efficient public health surveillance and guiding timely responses to COVID-19.We present a general framework for using existing data to estimate the efficiency gain from using a covariate-adjusted estimator of a marginal treatment effect in a future randomized trial. We describe conditions under which it is possible to define a mapping from the distribution that generated the existing external data to the relative efficiency of a covariate-adjusted estimator compared to an unadjusted estimator. Under conditions, these relative efficiencies approximate the ratio of sample size needed to achieve a desired power. We consider two situations where the outcome is either fully or partially observed and several treatment effect estimands that are of particular interest in most trials. For each such estimand, we develop a semiparametrically efficient estimator of the relative efficiency that allows for the application of flexible statistical learning tools to estimate the nuisance functions and an analytic form of a corresponding Wald-type confidence interval. We also propose a double bootstrap scheme for constructing confidence intervals.